Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitaxsentan in PAH (STRIDE-1)
NCT00034307Phase 3Unknown
- Sponsor
- ICOS Corporation
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of pirfenidone in pulmonary arterial hypertension (PAH), sponsored by ICOS Corporation. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00034307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034307.